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Background: Framingham Vascular Age is a simple age-normed score for cardiovascular risk that can be used to help communicate risk to patients and identify those that are relatively higher risk. Although ‘Normal’ age-related cognitive decline has been associated with cardiovascular risk factors, its relationship with Framingham vascular age has not been studied.
Objective: To cross-sectionally assess association between Framingham vascular age and cognition, in an older adult cohort. 
Methods: 346 participants (57 ± 10 years), without neurological or psychiatric disorders or clinical manifestations of cardiovascular disease were studied. Cognition was evaluated using the Brief Memory and Executive Test, which is specific and sensitive in the detection of the cognitive deficit seen in cerebral small vessel disease. The relationship between Framingham Vascular Age and cognitive performance was determined using General Linear Models to control for the effects of chronological Age, Premorbid Intelligence and Ethnicity.
Results: Framingham Vascular age was associated with poorer performance on both Memory and Executive Function/Processing Speed indices (p=0.019 and p<0.001, respectively). Although the association with Executive Function/Processing Speed was stronger than with memory (correlation coefficients: -0.509 vs. -0.277), there was no difference on formal statistical comparison.
Conclusions: Framingham Vascular age is associated with decline in Executive Function/Processing Speed and to a lesser degree with Memory in a cohort of middle-aged and elderly individuals. Vascular age may help identify those most at risk of age-related cognitive decline with implications for communicating to patients the morbidity associated with cardiovascular risk factors. 
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Introduction
Old age can be accompanied by ‘normal’ cognitive decline, which may interfere with daily living. This age-related cognitive decline has been associated with common vascular risk factors that contribute to cerebrovascular disease, such as hypertension (Vicario, del Sueldo, Zilberman, & Cerezo, 2011), diabetes mellitus (Nandipati, Luo, Schimming, Grossman, & Sano, 2012) and smoking (Sabia et al., 2012). Midlife hypertension, diabetes, smoking and obesity have been associated with increased rate of cerebral atrophy and decline in executive function and processing speed (Debette et al., 2011; Wiederkehr, Laurin, Simard, Verreault, & Lindsay, 2009). The major cerebrovascular pathology underlying age-related cognitive impairment and dementia is Cerebral Small Vessel Disease, which can be visualised on MRI as T2-white matter hyperintensities (WMH), and small subcortical infarcts (de Leeuw et al., 2002).

With the increasingly elderly population and burden of cognitive decline, there is an increasing focus on the contribution of vascular risk factors and their treatment (Valenti, Pantoni, & Markus, 2014). To prevent age-related cognitive decline, it is useful to be able to identify those most at risk to allow for more targeted interventions. The European guidelines on cardiovascular disease prevention recommend using risk age algorithms rather than absolute risk for estimating cardiovascular risk especially in patients where absolute risk is relatively low, and it has been shown that this can identify more patients who need preventative interventions (Piepoli et al., 2016; Wibetoe et al., 2018). Framingham Cardiovascular risk has been associated with poorer cognitive function (Joosten et al., 2013). Vascular age is an age-norm for Framingham cardiovascular risk, allowing for easy identification of individuals with a higher than average cardiovascular risk by comparing a patient’s vascular age to their chronological age (D’Agostino et al., 2008; Sharma et al., 2015; Tay, Nurjono, & Lee, 2013). It was developed to facilitate easier understanding of the concept of risk and is calculated using an algorithm which takes into account age, gender and modifiable cardiovascular risk factors (D’Agostino et al., 2008). Vascular age may assist in communication of risk of morbidity to patients as their chronological age becomes an easy baseline comparison to understand. It has been shown that vascular age is more emotionally impactful than absolute risk, and encourages larger improvements in modifiable risk factors (Cuende, Cuende, & Calaveras-Lagartos, 2010; Lopez-Gonzalez et al., 2015; Soureti, Hurling, Murray, van Mechelen, & Cobain, 2010). 





Recruitment of participants was approved by London Bridge Research Ethics Committee (11/LO/0636) and informed written consent was obtained from all participants prior to participation. Participants were recruited as a control population to determine population norms for the Brief Memory and Executive Test (BMET) (Brookes, Hannesdottir, Lawrence, Morris, & Markus, 2012; Brookes, Hollocks, Khan, Morris, & Markus, 2015).

Four hundred and ninety control participants who had no past medical history of any central neurological or psychiatric condition were recruited from local GP practices and volunteer groups. A further inclusion criteria was fluency in English to allow cognitive testing. Based on the reference Framingham cohort, participants were excluded if they had symptomatic cardiovascular disease (D’Agostino et al., 2008). Medical information was based on participants’ medical records and self-reporting. Demographics and vascular risk factors were recorded on a standardised proforma. Systolic blood pressure was recorded as an average of three physician-recorded measurements taken with the participants seated and rested. Medications including antihypertensive drugs were recorded. Participants were categorised as either current smokers or past/non-smokers, and Diabetes was determined based on a prior clinical diagnosis. Weight and height were measured and Body Mass Index was defined as [Weight (kg)/(Height (m)2)].

Cognitive Measures
Brief Memory and Executive Test (BMET)
Many widely used screening tests, such as the mini-mental state examination (MMSE), are insensitive to executive function. Cognition was therefore assessed using the BMET, a validated brief clinical screening test, designed to identify impairment in Executive Function and Processing speed, seen in symptomatic patients with Cerebral Small Vessel Disease (Brookes et al., 2012, 2015). It consists of two groups of eight subtests, split according to the cognitive domain that they primarily measure: a) Executive Function and Processing speed: three sequencing tasks (motor-sequencing, letter-sequencing, and number-letter sequencing) and a coding test involving rapid letter-number matching; and b) Orientation and Memory: orientation, five-item immediate repetition, five-item recall, and five-item recognition memory. 

National Adult Reading Test (NART-R)
The NART-R is a validated measure of pre-morbid intelligence (Nelson & Willison, 1991), and was used as a baseline measure of cognition. The test involves reading 50 irregularly spelt words for assessment of pronunciation. To increase reliability, assessment of pronunciation was standardised by having experimenters familiarise themselves with an audio pronunciation guide. 
Framingham Vascular Age
The Framingham Vascular Age score was calculated using a previously published algorithm incorporating several established risk factors (Age, Gender, Systolic Blood Pressure, on antihypertensive medication, Smoking, Type 2 Diabetes Mellitus, Body Mass Index) (D’Agostino et al., 2008). 

Statistical analysis
Raw BMET scores were used for more granularity to detect ‘normal’ age-related cognitive decline (Brookes et al., 2012).  Performance in the Orientation subtest of the BMET was excluded from further analysis because of poor variance between participant scores, suggestive of a ceiling effect in a healthy control sample. For ease of interpretation, the latency scores on the sequencing subtests were reflected, so that a larger number would equate to a better score, in line with the other subtests. To reduce the effect of measurement error and task-specific influences and increase the reliability of the cognitive measures, Principal Components Analysis (PCA) was used to derive composite scores. The subtests were split into two groups based on an a priori understanding of cognitive structure applied to this context (Executive Function/Processing Speed versus Memory), and a traditional PCA was conducted on each group. Principal Components were only extracted if they had an eigenvalue significantly above 1, producing a standardised cognitive index for each group of subtests. 

Correlations between each cognitive index and Vascular Age were determined by Pearson correlation coefficients. General Linear Models were used to determine the cross-sectional association between Vascular Age and each of the Executive Function/Processing Speed and Memory composites. When comparing two effects (i.e. vascular age on Executive Function/Processing Speed and vascular age on memory), a statistical test is required on their difference (Nieuwenhuis, Forstmann, & Wagenmakers, 2011). Therefore, to determining whether one cognitive index was more strongly associated with vascular age, the difference between the two indices was analysed. Ethnicity (classed as white or non-white) was included as a covariate because of its association with cardiovascular risk (Chaturvedi, 2003). Premorbid intelligence, as measured by the NART-R, was included as a covariate to control for its contributions to a cognitive reserve (Starr & Lonie, 2008). Chronological age was included as a covariate to control for any other age-related effects on cognition. Partial Eta-squared (n2), which varies between 0 and 1 is reported as a measure of effect size. The significance threshold of explanatory variables was set a priori (p=0.05). To produce the most parsimonious models without overfitting, a process of backwards elimination of least significant predictors was used. Assumptions of little multicollinearity between variables (Variance Inflation factor <5), homoscedasticity and normality of residuals, were all checked. The models showed the same patterns for males and females, so only overall models are presented.






To ensure the validity of Framingham Vascular Age, participants were excluded if they had a self-reported history of symptomatic cardiovascular disease (N=2), or if their age was outside the age-range (30 to 74) of participants in the ‘normal’ reference Framingham cohort (N=116) [22]. An additional 28 participants were omitted due to missing data; therefore 346 participants (54% female) were included in this study. The 28 participants omitted due to missing data did not significantly differ in age or cardiovascular risk factors from those included. The participants were predominantly white in ethnicity (88%). Descriptive statistics of the participants and their performance on neuropsychological tests are detailed in Table 1. Participants were aged 57±10 years and age was roughly uniformly distributed (Figure 1). Participants were overweight on average (BMI 26±5) but were on average normotensive (systolic blood pressure 131±17). Only 5% (17) of participants had type 2 diabetes mellitus, 11% (39) were current smokers and 20% (68) were on prescribed antihypertensive medication. Participants had an average Framingham vascular age of 64±15 years.

(Insert Table 1 here)

Principal Components Analyses
Principal Components Analysis (PCA) produced a single standardised (z) component solution for each group of subtests. PCA of the Executive Function/Processing Speed subtests produced an Executive Function/Processing Speed index, accounting for 58.7% of the total variance with the following loadings: Motor Sequencing (0.623), Letter-Sequencing (0.838), Number-Letter Sequencing (0.757) and Letter-Number Matching (0.828). PCA of the memory subtest scores produced a Memory index, which accounted for 56.9% of the total variance with the following loadings: Five-Item Immediate Repetition (0.403), Five-Item Recall (0.880) and Five-Item Recognition (0.878).

Vascular Age and cognitive indices
On bivariate analysis, statistically significant negative correlations were found between Framingham Vascular Age and each cognitive index (Table 2).

(Insert Table 2 here)

In the General Linear Models (Table 3), Vascular Age (β coefficient ± Standard Error=           -0.019 ± 0.005, p<0.001) was negatively associated with the Executive Function/Processing Speed index, after controlling for chronological Age, Premorbid Intelligence and Ethnicity. The amount of variance accounted for in the Executive Function/Processing Speed scores in this model was 0.396. Premorbid Intelligence was positively associated with the Executive Function/Processing Speed index (0.035 ± 0.006, p<0.001), whereas Age was negatively associated (-0.026 ± 0.008, p<0.001). The effect sizes (Partial Eta Squared) of each covariate included in the model can be seen in Table 3. Vascular Age had a larger effect than Age (Partial Eta Squared=0.042 compared to 0.035).

(Insert Table 3 here)

Vascular Age (-0.014 ± 0.006, p= 0.019) was negatively associated with the Memory index, when controlling for chronological Age, Ethnicity and Premorbid Intelligence. The amount of variance accounted for in the memory scores in this model was 0.114. Premorbid Intelligence was positively associated with the Memory index (0.020 ± 0.007, p=0.004). 

Vascular Age was not a significant predictor of the difference between the cognitive indices, causing overfitting when controlling for Age, Premorbid Intelligence and Ethnicity (Table 3). 

Discussion
In this study of middle-aged and older individuals free of stroke and cardiovascular disease, we found that Framingham Vascular Age was associated with impaired cognitive function. Specifically, we found it was associated with poorer performance on both Executive Function/Processing Speed and Episodic memory tasks. Although the strength of the association with executive function/processing speed was greater, on formal statistical comparison there was no difference after controlling for chronological Age. These findings were in a cohort of participants with a low burden of vascular risk factors (Table 1).

Our results are consistent with previous studies showing an association between absolute Framingham cardiovascular risk and poorer cognitive function in a middle-aged and elderly population (Beason-Held et al., 2012; Joosten et al., 2013; Kaffashian et al., 2011). This has similarly been shown to be the case for the Framingham absolute stroke risk score, which has also been correlated with a predictive risk score for developing late-life dementia (Dregan, Stewart, & Gulliford, 2013; Jefferson et al., 2015; Kaffashian et al., 2013). However, none of these studies have assessed whether this association stands for vascular age, which is recommended has been recommended as a tool for communicating risk to patients (Piepoli et al., 2016). Moreover, there is conflicting data on whether vascular risk factors are also associated with impairment in memory (Debette et al., 2011; Jefferson et al., 2015; Knopman et al., 2001; Wiederkehr et al., 2009). Discordant results may be partially attributed to the use of a cognitive screening test to assess memory which also rely on executive function. This problem may be reduced by using multiple tests for memory and executive function as we have done in this study and using dimension reduction methods to derive common constructs. Common constructs tend to be more reliable cognitive measures, yet only one of these previous studies utilised the technique (Wiederkehr et al., 2009). 

Sub-cortical white matter integrity is important for intact executive function and processing speed (Charlton, McIntyre, Howe, Morris, & Markus, 2007), and damage to this white matter in Cerebral Small Vessel Disease is an important mechanism underlying Vascular Cognitive Impairment and Vascular Dementia, as a result of diffuse disruption of white matter networks (Lawrence, Chung, Morris, Markus, & Barrick, 2014; Tuladhar et al., 2016). This cortical-subcortical “disconnection” due to white matter damage is also thought to be important in age-related cognitive decline (O’Sullivan et al., 2001). Executive function and Processing Speed are the cognitive domains most affected by Cerebral Small Vessel Disease and a recent meta-analysis concluded that although Vascular Cognitive Impairment can affect all cognitive domains, these are most markedly impaired (Vasquez & Zakzanis, 2015).

To our knowledge this is the first study to determine an association between Framingham Vascular Age and ‘normal’ age-related cognitive decline in an otherwise healthy elderly cohort. An inherent disadvantage of cross-sectional studies is that they only allow between-person comparisons, so there is the risk of confounding between actual effects of aging and cohort effects. Further longitudinal studies will help resolve this issue. Cognition was evaluated using the Brief Memory and Executive Test, which is specific and sensitive in the detection of the cognitive deficit seen in cerebral small vessel disease, but more comprehensive neuropsychological assessment may reveal further detail on the impact of vascular age on cognition (Brookes et al., 2015). Patient medical records and self-reporting were used to establish medical information for calculation of vascular age and exclude patients with central neurological and psychiatric conditions. Although it is possible that some participants may have undiagnosed conditions, given our sample size and the nature of this study, we feel are methods are of sufficient accuracy.
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Framingham Vascular Age components	
Gender (% females)	186 (54)
Age (Mean years± SD)	57±10 (40-74)
Body Mass Index (Mean kg/m2± SD)	26±5
Systolic Blood Pressure (Mean mmHg± SD)	                   131±17	
Antihypertensive medication (%)	68 (20)
Current Smokers (%)	39 (11)
Diabetes mellitus (%)	17 (5) 
Framingham Vascular Age (Mean years± SD)	64±15 (33-86)
Test performance	
Memory and Orientation subtests	
Orientation (mean± SD)	10±0.3
Five Item Repetition (mean± SD)	15±1
Five Item Memory (Delayed Recall) (mean± SD)	4±1
Five Item Memory (Delayed Recognition) (mean± SD)	4±1
Executive Function and Processing speed subtests	
Letter-Number Matching (mean± SD)	30±6
Motor Sequencing (mean± SD)	9±5
Letter Sequencing (mean± SD)	28±9
Number-Letter Sequencing (mean± SD)	37±17
NART-R (mean± SD)	39±8
Ethnicity (% white)	305 (88)
Table 1. Descriptive statistic: Vascular risk factors and cognitive measure performance










    Table 2. Pearson Correlation Coefficients between predictors and cognitive indices







Table 3. General Linear Models for Memory and Executive Function/Processing Speed
Dependent Variable:  Executive Function/Processing Speed index	





Dependent Variable:  Memory index		





Dependent Variable: Executive Function/Processing Speed index - Memory index
Parameter		β		Standard Error		t		p-value (2-tailed)	Partial Eta Squared
Vascular Age		-0.005		0.007		-.739		.461	.002
Age		-.019		.010		-1.878		.061	.010
Premorbid Intelligence		.015		.008		1.820		.070	.010
Ethnicity		-.289		.194		-1.491		.137	.006
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